bronchitis%20-%20uncomplicated%20acute
BRONCHITIS - UNCOMPLICATED ACUTE
Uncomplicated acute bronchitis is a self-limiting infection of the trachea and bronchi that usually lasts for 1 to 3 weeks. A healthy patient experiences sudden onset of cough, with or without sputum production.
It is an inflammatory response to infections of the bronchial epithelium of the large airways of the lungs that begins with mucosal injury, epithelial cell damage and release of proinflammatory mediators.
There is transient airflow obstruction and bronchial hyperresponsiveness.
Purulence can result from either bacterial or viral infection.
Drug Information

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Infections caused by susceptible organisms in lower resp tract (eg, bronchitis, pneumonia), skin & soft ti...

Indication: Tab/powd for oral susp Lower resp tract infections including bronchitis & pneumonia; skin & soft tissu...

Indication: Acute & chronic bronchopulmonary diseases associated w/ abnormal mucus secretion & impaired mucus tran...

Indication: Acute & chronic diseases of the resp tract especially chronic bronchitis, asthmatoid bronchitis, bronchial...

Indication: Reduction of sputum viscosity.

Axcel Dextrozine
dextromethorphan hydrobromide + promethazine hydro...

Indication: Relief of congestion & dry irritating cough eg, those associated w/ common cold, upper resp tract infectio...

Axcel Erythromycin ES
erythromycin ethylsuccinate

Indication: Upper & lower resp tract infections caused by Strep pyogenes & Strep pneumoniae; pertussis caused by B...

Indication: Relief of unproductive or irritating coughs associated w/ common cold, sinusitis, flu & upper resp tract i...

1  /  16
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 4 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.